Results of the PATHWAY study of AspireAssist® have been published.

Posted Dec 8, 2016.

Results of the PATHWAY study of AspireAssist®, a 171-subject, multicentre randomized control trial in the US, have been published yesterday in the American Journal of Gastroenterology, which mark a significant milestone for the AspireAssist paving the way for worldwide acceptance and adoption.
The published results show that patients lost an average of 37% of their excess weight after 52 weeks, with a very low incidence of serious adverse events. Clinically relevant improvement in the treatment group was seen in HbA1C (-0.36% relative to 5.7% baseline, P <0.0001), triglycerides (−9.9%, P =0.02), and high-density lipoprotein cholesterol (+8.1%, P =0.0001), at week 52 compared with baseline. Read the press release here.